[¹⁸F]AlF-NOTA-FAPI-04

Phase 2

PPeking Union Medical College Hospital

[¹⁸F]AlF-NOTA-FAPI-04 is one of 29 therapeutic programs targeting Cardiomyopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

CardiomyopathyRecruiting

CardiomyopathyPhase 2

Recruiting

Competition

Competitive Landscape

35 competitors in Cardiomyopathy

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

1 2

Bayer Aspirin

Bayer

Approved

1 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 4

Cordarone

WWyeth-Lederle Vaccines

Approved

1 5

Zocor

OOrganon and Co

Approved

1 6

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 7

Rayos

Natrecor

Inpefa

LLexicon Pharmaceuticals

Approved

—10

Ranexa

MMenarini International Operations Luxembourg SA

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Cardiomyopathy

NCT07878338

Clinical

Trials by Indication[1]

Cardiomyopathy1 trial

Mapping Myocardial Fibroblast Activation With FAPI PET Imaging in Nonischemic Cardiomyopathy

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07878338·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [¹⁸F]AlF-NOTA-FAPI-04. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [¹⁸F]AlF-NOTA-FAPI-04. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: PPeking Union Medical College Hospital

[¹⁸F]AlF-NOTA-FAPI-04

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News